For research use only. Not for therapeutic Use.
RLY-2608(CAT: I040592) is a highly selective, allosteric small-molecule inhibitor targeting oncogenic mutant forms of phosphoinositide 3-kinase alpha (PI3Kα), including H1047R and E545K. Designed to minimize inhibition of wild-type PI3Kα, RLY-2608 offers a favorable safety profile with reduced off-target toxicity. It interferes with mutant PI3Kα-driven signaling pathways critical in various cancers, such as breast and ovarian tumors harboring PIK3CA mutations. RLY-2608 demonstrates strong anti-proliferative activity in preclinical models and is suitable for use in combination strategies to overcome resistance mechanisms in PI3Kα-driven malignancies. It serves as a valuable tool for cancer biology and targeted therapy research.
| CAS Number | 2733573-94-7 |
| Synonyms | N-[(3R)-3-(2-chloro-5-fluorophenyl)-6-(5-cyano-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-oxo-2,3-dihydroisoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide |
| Molecular Formula | C29H14ClF5N6O2 |
| Purity | ≥95% |
| IUPAC Name | N-[(3R)-3-(2-chloro-5-fluorophenyl)-6-(5-cyano-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-oxo-2,3-dihydroisoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide |
| InChI | InChI=1S/C29H14ClF5N6O2/c30-21-3-1-16(31)10-19(21)26-25-20(28(43)40-26)7-13(18-2-4-24-37-12-38-41(24)23(18)11-36)8-22(25)39-27(42)14-5-15(29(33,34)35)9-17(32)6-14/h1-10,12,26H,(H,39,42)(H,40,43)/t26-/m0/s1 |
| InChIKey | VYWRYBZVVSPTQN-SANMLTNESA-N |
| SMILES | C1=CC(=C(C=C1F)C2C3=C(C=C(C=C3NC(=O)C4=CC(=CC(=C4)F)C(F)(F)F)C5=C(N6C(=NC=N6)C=C5)C#N)C(=O)N2)Cl |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
